Evidence map›Paper›PMID 28453843›Full record

Trial reportThe Journal of infectious diseases2017

Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.

Priyanka Uprety, Jane C Lindsey, Myron J Levin, Kaitlin Rainwater-Lovett, Carrie Ziemniak, Mutsa Bwakura-Dangarembizix, Susan S Kaplan, Micki Nelson, Amanda Zadzilka, Adriana Weinberg and 1 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Priyanka UpretyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Jane C LindseyCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
Myron J LevinSection of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA.
Kaitlin Rainwater-LovettDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carrie ZiemniakDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mutsa Bwakura-DangarembizixDepartment of Pediatrics and Child Health, University of Zimbabwe College of Health Sciences, Zimbabwe.
Susan S KaplanMerck & Co, Inc, Kenilworth, New Jersey, USA.
Micki NelsonMerck & Co, Inc, Kenilworth, New Jersey, USA.
Amanda ZadzilkaFrontier Science and Technology Research Foundation, Amherst, New York, USA.
Adriana WeinbergSection of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA.
Deborah PersaudW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Johns Hopkins Medicine · USJohns Hopkins University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of Colorado Anschutz Medical Campus · USCancer Research And Biostatistics · USFrontier Science & Technology Research Foundation · USUniversity of Zimbabwe · ZW

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
Early Antiretroviral Therapy and HIV Remission in Perinatal InfectionR01HD080474 · NICHD · JOHNS HOPKINS UNIVERSITY · PI BRYSON, YVONNE J., LUZURIAGA, KATHERINE F · 2014 to 2018
$6.5M
NCATS NIH HHS UL1 TR001453NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI106716NICHD NIH HHS R01 HD080474
6 · The paper itself

Abstract

Biomarkers of inflammation and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)–infected (and 116 HIV-exposed but uninfected (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial. Prevaccination, HIV-1+ infants had significantly higher concentrations of interferon γ (IFNγ), interleukin1β, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14 compared with HEU infants. Postvaccination concentrations of neutralizing antibodies to RV5 were negatively correlated with prevaccination concentrations of IL-10 (RV5 surface proteins G1 and P1) and IFNγ (G1) in the HIV-1+ infants, whereas antirotavirus immunoglobulin A (IgA) levels were not. Heightened inflammation and immune activation in HIV-1+ infants did not alter IgA responses associated with protection from rotavirus disease.

Indexed as

Antibodies, NeutralizingAntibodies, ViralAntiretroviral Therapy, Highly ActiveBiomarkersBotswanaCD4 Lymphocyte CountCytokinesDouble-Blind MethodFemaleHIV-1HIV InfectionsHumansImmunoglobulin AInfantInflammationMaleAntibodies, NeutralizingAntibodies, ViralBiomarkersCytokinesImmunoglobulin ARotavirus Vaccinesantiretroviral therapyimmune activationinflammationPerinatal HIV-1 infectionrotavirus vaccine

Identifiers

PMID28453843
PMCPMC5407055
OpenAlexW2587182749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.